Dallas Tissue Research
Alex Van Engelenburg is an experienced leader in the biotechnology sector, currently serving as President and CEO of Dallas Tissue Research since May 2021. Prior to this role, Alex held the position of Chief Business Officer at HistoTox Labs for a brief period from January 2021 to July 2021, after spending over a decade as Director of Operations at HistoTox Labs Inc. from June 2010 to January 2021. Alex's academic background includes a degree in Biochemistry and MCDB from the University of Colorado Boulder, completed in 2009.
This person is not in any teams
Dallas Tissue Research
DTR is a CRO specialized in non-clinical histopathology services supported by advanced staining and analysis. Our experienced team of scientists, led by pathologists, collaborate with you to help investigate your novel targets, select and evaluate new models, and understand therapeutic efficacy.